Literature DB >> 24613848

Sine oculis homeobox homolog 1 promotes α5β1-mediated invasive migration and metastasis of cervical cancer cells.

Dan Liu1, Xiao-Xue Zhang1, Dong-Yi Wan1, Bi-Xin Xi1, Ding Ma1, Hui Wang1, Qing-Lei Gao2.   

Abstract

Sine oculis homeobox homolog 1 (SIX1) has been supposed to be correlated with the metastasis and poor prognosis of several malignancies. However, the effect of SIX1 on the metastatic phenotype of tumor cells and the underlying mechanisms were still unclear to date. Here we report that SIX1 can promote α5β1-mediated metastatic capability of cervical cancer cells. SIX1 promoted the expression of α5β1 integrin to enhance the adhesion capacity of tumor cells in vitro and tumor cell arrest in circulation in vivo. Moreover, higher expression of SIX1 in tumor cells resulted in the increased production of active MMP-2 and MMP-9, up-regulation of anti-apoptotic genes (BCL-XL and BCL2) and down-regulation of pro-apoptotic genes (BIM and BAX), thus promoting the invasive migration and anoikis-resistance of tumor cells. Importantly, blocking α5β1 abrogated the regulatory effect of SIX1 on the expression of these genes, and also abolished the promotional effect of SIX1 on invasive capability of tumor cells. Furthermore, knock-down of α5 could abolish the promoting effect of SIX1 on the development of metastatic lesions in both experimental and spontaneous metastasis model. Therefore, by up-regulating α5β1 expression, SIX1 not only promoted the adhesion capacity, but also augmented ECM-α5β1-mediated regulation of gene expression to enhance the metastatic potential of cervical cancer cells. These results suggest that SIX1/α5β1 might be considered as valuable marker for metastatic potential of cervical cancer cells, or a therapeutic target in cervical cancer treatment.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Integrin; Invasion; Metastasis; SIX1; α5β1

Mesh:

Substances:

Year:  2014        PMID: 24613848     DOI: 10.1016/j.bbrc.2014.03.002

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  7 in total

1.  Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis.

Authors:  Hengbo Zhou; Melanie A Blevins; Jessica Y Hsu; Deguang Kong; Matthew D Galbraith; Andrew Goodspeed; Rachel Culp-Hill; Michael U J Oliphant; Dominique Ramirez; Lingdi Zhang; Jennyvette Trinidad-Pineiro; Lesley Mathews Griner; Rebecca King; Elena Barnaeva; Xin Hu; Noel T Southall; Marc Ferrer; Daniel L Gustafson; Daniel P Regan; Angelo D'Alessandro; James C Costello; Samarjit Patnaik; Juan Marugan; Rui Zhao; Heide L Ford
Journal:  Cancer Res       Date:  2020-04-27       Impact factor: 12.701

2.  MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.

Authors:  Mathieu Francois Derouet; Geoffrey Liu; Gail Elizabeth Darling
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

Review 3.  Disintegrins from snake venoms and their applications in cancer research and therapy.

Authors:  Jéssica Kele Arruda Macêdo; Jay W Fox; Mariana de Souza Castro
Journal:  Curr Protein Pept Sci       Date:  2015       Impact factor: 3.272

4.  Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer.

Authors:  Xiaoxue Zhang; Dan Liu; Mengchen Li; Canhui Cao; Dongyi Wan; Bixin Xi; Wenqian Li; Jiahong Tan; Ji Wang; Zhongcai Wu; Ding Ma; Qinglei Gao
Journal:  J Hematol Oncol       Date:  2017-01-23       Impact factor: 17.388

5.  SIX1 coordinates with TGFβ signals to induce epithelial-mesenchymal transition in cervical cancer.

Authors:  Shu-Hua Sun; Dan Liu; Yun-Te Deng; Xiao-Xue Zhang; Dong-Yi Wan; Bi-Xin Xi; Wei Huang; Qian Chen; Meng-Chen Li; Ming-Wei Wang; Fei Yang; Ping Shu; Ke-Zhi Wu; Qing-Lei Gao
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

6.  C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.

Authors:  Dan Liu; Xiao-Xue Zhang; Meng-Chen Li; Can-Hui Cao; Dong-Yi Wan; Bi-Xin Xi; Jia-Hong Tan; Ji Wang; Zong-Yuan Yang; Xin-Xia Feng; Fei Ye; Gang Chen; Peng Wu; Ling Xi; Hui Wang; Jian-Feng Zhou; Zuo-Hua Feng; Ding Ma; Qing-Lei Gao
Journal:  Nat Commun       Date:  2018-04-30       Impact factor: 14.919

7.  Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.

Authors:  Yingyan Han; Peng Wu; Zhi Wang; Zeyu Zhang; Shujuan Sun; Jia Liu; Song Gong; Peipei Gao; Tomoo Iwakuma; Miguel Angel Molina-Vila; Benjamin Ping-Chi Chen; Yu Zhang; Teng Ji; Qingqing Mo; Pingbo Chen; Junbo Hu; Shixuan Wang; Jianfeng Zhou; Hua Lu; Qinglei Gao
Journal:  EBioMedicine       Date:  2019-01-20       Impact factor: 8.143

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.